Spotted fever group rickettsiosis acquired in sub-Saharan Africa was the most common rickettsial disease observed.
We investigated epidemiologic and clinical aspects of rickettsial diseases in 280 international travelers reported to the GeoSentinel surveillance Network during 1996–2008. Of these 280 travelers, 231 (82.5%) had spotted fever (SFG) rickettsiosis, 16 (5.7%) scrub typhus, 11 (3.9%) Q fever, 10 (3.6%) typhus group (TG) rickettsiosis, 7 (2.5%) bartonellosis, 4 (1.4%) indeterminable SFG/TG rickettsiosis, and 1 (0.4%) human granulocytic anaplasmosis. One hundred ninety-seven (87.6%) SFG rickettsiosis cases were acquired in sub-Saharan Africa and were associated with higher age, male gender, travel to southern Africa, late summer season travel, and travel for tourism. More than 90% of patients with rickettsial disease were treated with doxycycline, 43 (15.4%) were hospitalized, and 4 had a complicated course, including 1 fatal case of scrub typhus encephalitis acquired in Thailand.
Rickettsial diseases are acute and potentially severe zoonotic infections caused by obligate intracellular, gram-negative bacteria belonging to the order Rickettsiales. The taxonomy of Rickettsiales is complex and continues to be updated, but currently the agents of rickettsial diseases are classified as belonging to 4 distinct genera:
Rickettsial diseases are increasingly being recognized among international travelers (
GeoSentinel is a global network aimed at surveying ill international travelers and was established in 1995 through the International Society of Travel Medicine and the Centers for Disease Control and Prevention. The 41 current GeoSentinel sites contribute clinician-based, anonymous information on all ill travelers seen that is entered in a structured query language database at a central data center. Data collected include demographic information, recent travel history, reason for travel, outpatient or inpatient status, whether the patient was seen during or after travel, whether the patient traveled independently versus organized travel (i.e., travel with a tour group), whether the patient had pretravel encounter with a healthcare provider, patient symptoms, and diagnosis. All GeoSentinel sites use the best reference diagnostic methods available in the country where the site is located. The diagnosis, which may be reported as confirmed, probable, or suspected, is chosen from a standardized list of >500 possible etiologic and syndromic diagnoses, 11 of which refer to rickettsial diseases. Patients may receive several diagnoses, some of which describe well-known complications of rickettsial diseases, e.g., acute renal failure, acute encephalitis, acute respiratory distress syndrome, and death (
Data entered into the GeoSentinel database from June 1996 through December 2008 were reviewed. Only travelers seen with confirmed or probable diagnoses were included in the analysis. Cases of rickettsial diseases were defined according to the criteria mentioned below. A subanalysis, comparing SFG rickettsioses with other diseases in ill returnees from sub-Saharan Africa, was also performed (
Study design with main study (above dotted line) and substudy (below dotted line) of spotted fever group (SFG) rickettsiosis acquired in sub-Saharan Africa, 1996–2008.
A microbiologic diagnosis of recent rickettsial disease was in most cases based on immunofluorescence antibody (IFA) tests and, occasionally, on PCR and Western blot. Diagnostic criteria of recent infection by IFA tests were either a 4-fold increase of immunoglobulin (Ig) G or IgM titers in paired serum samples drawn
We included all cases of confirmed rickettsial disease defined as a traveler with pertinent travel history and clinical signs, and microbiologic test results supporting recent infection. For SFG rickettsiosis and scrub typhus we also included probable cases defined as a traveler with pertinent travel history and clinical signs including
All data were analyzed using SAS software, version 9 (SAS Institute, Cary, NC, USA). Comparison of travelers to sub-Saharan Africa with SFG rickettsioses with all other ill travelers to the same destination used the Student
Proportionate morbidity for SFG rickettsiosis acquired in sub-Saharan Africa was defined as the number of cases as a proportion of all ill returned travelers from the region. Analysis of case reports over time was based on monthly proportionate morbidity, i.e., the number of patients with SFG rickettsiosis as a proportion of the number of all ill returned travelers attending any GeoSentinel site in that month. The monthly seasonality was based on aggregate data for that month over all years. The annual proportionate morbidity for SFG rickettsiosis acquired in southern Africa from 1999 through 2008 was estimated in a similar way based on relevant cases for each year. The Cochran-Armitage test was used for testing trend over years. This statistic tests for trend in binomial proportions across levels of a single factor or covariate and is appropriate for a contingency table where the response variable has 2 levels and the explanatory variable is ordinal. A 1-sided p value <0.05 would indicate a decreasing (with a negative statistic) or increasing (with a positive statistic) trend.
We identified 99,355 travelers who sought medical care at a GeoSentinel site during June 1996–December 2008. Among the 47,915 case-patients who met the study inclusion criteria, 280 (0.6%) had a diagnosis of rickettsial disease (
| Destination | No. travelers | ||||||
|---|---|---|---|---|---|---|---|
| SFG rickettsiosis | TG rickettsiosis | Indeterminate SFG/TG rickettsiosis | Scrub typhus | Anaplasmosis | Acute Q fever | Bartonellosis | |
| Western Europe | 7 | 1 | 1 | 2 | 1 | ||
| Eastern Europe | 1 | ||||||
| North Africa | 3 | ||||||
| Sub-Saharan Africa | 197 | 1 | 5 | 1 | |||
| Middle East | 1 | 2 | 1 | ||||
| Northeast Asia | 2 | 1 | 1 | ||||
| South-central Asia | 5 | 1 | 1 | 5 | |||
| Southeast Asia | 3 | 6 | 2 | 9 | 1 | ||
| Australia/New Zealand | 1 | 1 | |||||
| Oceania | 1 | ||||||
| North America | 1 | ||||||
| Central America | 3 | ||||||
| Caribbean | 1 | 3 | |||||
| South America | |||||||
| Unknown | 6 | 1 | 1 | ||||
| Total | 231 | 10 | 4 | 16 | 1 | 11 | 7 |
*SFG, spotted fever group; TG, typhus group.
Of the 231 cases of SFG rickettsioses (146 confirmed and 85 probable) a total of 136 (58.9%) were men; the mean age was 43.4 years (median 45 years, range 33–53 years). Tourists comprised 182 (78.8%), 28 (12.1%) had traveled for business, 6 (2.6%) were visiting friends and relatives, and 14 (6.1%) had traveled for other reasons. One hundred ninety-seven (87.6%) case-patients were infected in sub-Saharan Africa; South Africa (n = 135), Zimbabwe (n = 13), and Tanzania (n = 7) were the 3 most commonly reported countries of exposure (
Analysis of demographic and exposure variables for the 197 travelers to sub-Saharan Africa with SFG rickettsiosis compared with 11,690 travelers to the same region with other diagnoses is shown in
| Variable | Travelers with SFG rickettsiosis, N = 197† | Travelers without SFG rickettsiosis, N = 11,690† | Univariate association | Multivariate model‡ | ||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | |||||
| Mean age, y | 43.9, n = 196 | 36.5, n = 11,608 | – | <0.0001 | 1.02 (1.01–1.03)§ | <0.0001 | ||
| Male gender, no. (%) | 115 (58.4), n = 197 | 6,105 (52.6), n = 11,599 | 1.26 (0.95–1.68) | 0.11 | 1.40 (1.02–1.92) | 0.035 | ||
| Travel to southern Africa,¶ no. (%) | 139 (70.6), n = 197 | 759 (6.5), n = 11,686 | 34.5 (25.18–47.28) | <0.0001 | 23.61 (16.86–33.07) | <0.0001 | ||
| Travel in late summer,# no. (%) | 89 (47.1), n = 189 | 4,220 (40.6), n = 10,402 | 1.30 (0.98–1.74) | 0.07 | 1.57 (1.15–2.15) | 0.005 | ||
| Travel duration >7 d, no. (%) | 173 (91.5), n = 189 | 9,661 (92.9), n = 10,402 | 0.83 (0.49–1.39) | 0.48 | 0.67 (0.38–1.18) | 0.164 | ||
| No pretravel clinic visit, no. (%) | 40 (21.7), n = 184 | 2,823 (26.5), n = 10,665 | 0.77 (0.54–1.10) | 0.15 | 0.98 (0.66–1.44) | 0.903 | ||
| Independent travel,** no. (%) | 34 (44.2), n = 77 | 4,100 (58.6), n = 6,993 | 0.56 (0.35–0.87) | 0.01 | 0.83 (0.56–1.25) | 0.373 | ||
| Tourism as reason for travel, no. (%) | 163 (82.7), n = 197 | 5,027 (43.0), n = 11,686 | 6.35 (4.38–9.21) | <0.0001 | 2.96 (1.97–4.45) | <0.0001 | ||
*SFG, spotted fever group; OR, odds ratio; CI, confidence interval.
†n = number of travelers for whom this information was available.
‡This model included all variables considered at univariate level because of their clinical relevance. The Hosmer and Lemeshow goodness-of-fit test for this model is p = 0.575.
§Odds ratio is for 1-y increase in age.
¶United Nations subregion comprising Botswana, Lesotho, Namibia, South Africa, and Swaziland.
Monthly proportionate morbidity (no. cases/1,000 travelers) of spotted fever group rickettsiosis acquired in sub-Saharan Africa, 1996–2008.
Annual proportionate morbidity (no. cases/1,000 travelers) of spotted fever group rickettsiosis acquired in southern Africa, 1996–2008. The dotted line indicates the mean value of 137/1,000 (13.7%).
The 10 travelers with TG rickettsiosis, of whom 6 were men, had a mean age of 28.0 years (median 25.5 years, range 20–50 years). Four case-patients were tourists, 2 were visiting friends and relatives, 1 was a business traveler, and 3 had traveled for other purposes. Southeast Asia, including 3 travelers infected in Indonesia, was the most common region of exposure (
Indeterminate SFG/TG rickettsiosis was diagnosed in 4 male tourists, 15, 50, 51, and 67 years of age, respectively. Two case-patients were infected in Southeast Asia (
The 16 travelers with scrub typhus (5 confirmed and 11 probable), of whom 10 were men, had a mean age of 36.6 years (median 32.5 years; range 26–67 years). Nine patients were infected in Southeast Asia (including Thailand, n = 4) and 5 in south-central Asia (including India, n = 3). Twelve patients were tourists, 1 was visiting friends and relatives, and 3 had traveled for business. The median time from travel to reporting to a GeoSentinel site was 9 days (range 2–25 days). Six case-patients were hospitalized. Encephalitis developed in 2 Singaporean travelers: a 42-year-old man, a tourist infected in Thailand in December 2007, died, and a 51-year-old man infected in Taiwan while traveling on business in April 2008 survived.
An uncomplicated case of human granulocytic anaplasmosis was seen in August 2008 in a 32-year-old US woman tourist to the Netherlands. The diagnosis was based on detection of intracellular morulae.
The 11 travelers with acute Q fever, including 4 men, had a mean age of 53.0 years (median 59 years; range 20–64 years). Sub-Saharan Africa, including 2 case-patients infected in Tanzania, was the most common region of exposure (
The 7 travelers with bartonellosis, including 3 males, had a mean age of 33.6 years (median 32 years, range 9–56 years). Three patients were infected in the Caribbean (
This study of 280 case-patients conducted over >12 years at 32 institutions on 5 continents represents the largest series of imported rickettsial diseases published to date. Noteworthy, SFG rickettsiosis was by far the most commonly diagnosed group of disease in our study. Numerous SFG rickettsioses occur throughout the world, the most important being Mediterranean spotted fever (with its variants Indian tick typhus, Astrakhan fever, and Israeli spotted fever) caused by
As shown here and by others (
Our series comprises 10 cases of TG rickettsioses, all of which were considered to represent murine typhus caused by
We also identified 16 cases of scrub typhus, a common disease in rural south and Southeast Asia and the Pacific. Before the present report, <30 cases of travel-associated scrub typhus had been published in the literature, and infection was predominantly acquired in Thailand and neighboring countries (
Human granulocytic anaplasmosis is a usually mild and nonspecific febrile illness commencing a few days after an
The ubiquitous Q fever, a zoonosis typically transmitted from domesticated mammals to humans by contaminated aerosols, is occasionally found in international travelers (
Bartonelloses are rarely reported in travelers but cases of Carrion disease caused by
With an overall incidence rate of 0.6% (and 1.5% of those travelers with fever), our analysis suggests that rickettsial diseases are uncommon in ill returnees. However, underdiagnosis is likely to be widespread, even at specialized institutions such as those associated with the GeoSentinel surveillance network. Few specific clinical signs exist in rickettsial diseases. Many cases have a nonfocal febrile disease of mild-to-moderate severity, accompanied by nonspecific results in routine blood tests (
Some rickettsial diseases are potentially malignant, but severe complications developed in only a few patients in the present series, and only 1 traveler died. There may be several reasons for this favorable outcome, including a large percentage of benign African tick bite fever cases, and a widespread empiric use of antirickettsial drugs in cases of suspected rickettsial disease. It is noteworthy that rickettsial organisms are inherently resistant to many antimicrobial drugs commonly used as treatment for acute fevers, including the β-lactams, and treatment of choice is tetracyclines, in particular, doxycycline. Fluoroquinolones and newer macrolides may also be useful (
Our study had limitations similar to those in other GeoSentinel studies, including a possible selection bias towards complicated and unusual cases (
In summary, the present study demonstrates the wide spectrum of rickettsial diseases that may be encountered in international travelers. Most infections are acquired in sub-Saharan Africa, where African tick bite fever is the predominate disease. The overall outcome is favorable but, because some rickettsial diseases may take a dire course, empirical treatment with an antirickettsial drug should always be considered whenever evaluating a traveler with an otherwise unexplained febrile disease who has recently returned from areas where these diseases are endemic.
In addition to the authors, the following members of the GeoSentinel Surveillance Network contributed data: Kevin C. Kain, University of Toronto, Toronto, Ontario, Canada; Phyllis E. Kozarsky and Carlos Franco-Paredes, Emory University, Atlanta, Georgia, USA; Louis Loutan and François Chappuis, University of Geneva, Geneva, Switzerland; Joseph Torresi and Graham Brown, Royal Melbourne Hospital, Melbourne, Victoria, Australia; DeVon C. Hale and Stefanie S. Gelman, University of Utah, Salt Lake City, Utah, USA; Alice Pérignon, Hôpital Pitié-Salpêtrière, Paris, France; Gerd-Dieter Burchard, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany; Mary E. Wilson, Harvard University, Cambridge, Massachusetts, USA; Fabrice Simon and Jean Delmont, Hôpital Nord, Marseille, France; William M. Stauffer and Patricia F. Walker, University of Minnesota, Minneapolis, Minnesota, USA; Poh Lian Lim and Annelies Wilder-Smith, Tan Tock Seng Hospital, Singapore; Jose Antonio Perez Molina, Hospital Ramon y Cajal, Madrid, Spain; Bradley A. Connor, Cornell University, Ithaca, New York, USA; Carmelo Licitra and Antonio Crespo, Orlando Regional Health Center, Orlando, Florida, USA; David O. Freedman, University of Alabama at Birmingham, Birmingham, Alabama, USA; Effrossyni Gkrania-Klotsas, Addenbrooke's Hospital, Cambridge, UK; Giampiero Carosi and Francesco Castelli, University of Brescia, Brescia, Italy; Marc Shaw, Worldwise Travelers Health and Vaccination Centre, Auckland, New Zealand; Prativa Pandey, CIWEC Clinic Travel Medicine Center, Kathmandu, Nepal; R. Bradley Sack and Robin McKenzie, Johns Hopkins University, Baltimore, Maryland, USA (Dec 1997–Aug 2007); Elizabeth D. Barnett, Boston University, Boston, Massachusetts, USA; Christina M. Coyle and Murray Wittner, Albert Einstein School of Medicine, Bronx, New York, USA; Stefan Hagmann and Andy Miller, Bronx-Lebanon Hospital Center, Bronx; Michael W. Lynch, Fresno International Travel Medical Center, Fresno, California, USA; Vanessa Field, InterHealth, London, UK; Michael D. Libman and J. Dick Maclean, McGill University, Montreal, Quebec, Canada; Alejandra Gurtman, Mount Sinai Medical Center, New York, New York, USA (Oct 2002–Aug 2005); Shuzo Kanagawa and Yasuyuki Kato, International Medical Center of Japan, Tokyo, Japan; and Patricia Schlagenhauf, Rainer Weber, and Robert Steffen, University of Zürich, Zürich, Switzerland.
We thank Elena Axelrod and Adam Plier for technical and organizational support, and David O. Freedman for valuable comments. We are also indebted to all GeoSentinel sites for providing data.
GeoSentinel, the Global Surveillance Network of the International Society of Travel Medicine, is supported by Cooperative Agreement U50/CCU412347 from the Centers for Disease Control and Prevention.
Dr Jensenius is a consultant in the Department of Infectious Diseases, Oslo University Hospital, Ullevål, Oslo, Norway. His research interest comprises arthropod-borne diseases in travelers.